ProCE Banner Activity

Expert Thoughts on Sequencing Therapy for Patients With HER2+ Metastatic Breast Cancer 

Clinical Thought

Are you up-to-date on current expert thoughts on optimal treatment sequencing for patients with HER2-positive metastatic breast cancer? Read this commentary to gain expert insights.

Released: January 29, 2025

Expiration: January 28, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Ian Krop, MD, PhD

Professor of Internal Medicine
Associate Cancer Center Director for Clinical Research
Chief Clinical Research Officer
Yale Cancer Center
New Haven, Connecticut

Ian Krop, MD, PhD: consultant/advisor/speaker: ALX Oncology, AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech/Roche, Novartis, Ottimo, Pfizer, Seagen.

Sarah L. Sammons, MD

Associate Director
Metastatic Breast Cancer Program
Susan F. Smith Center for Women’s Cancers
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Sarah L. Sammons, MD: researcher: Daiichi Sankyo, Relay Therapeutics, Seagen, Sermonix; consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Incyclix, Lilly, Novartis, Pfizer, Seagen, Sermonix.